Biomarker-based assessment of collagen cross-linking identifies patients at risk of heart failure more likely to benefit from spironolactone effects on left atrial remodelling. Insights from the HOMAGE clinical trial

S. Ravassa, B. Lopez, J.P. Ferreira, N. Girerd, E. Bozec, P. Pellicori, B. Mariottoni, F. Cosmi, M. Hazebroek, J.A.J. Verdonschot, J. Cuthbert, J. Petutschnigg, M.U. Moreno, S. Heymans, J.A. Staessen, B. Pieske, F. Edelmann, A.L. Clark, J.G.F. Cleland, F. ZannadJ. Diez*, A. Gonzalez*, HOMAGE Trial Committees and Investigators

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

4 Citations (Web of Science)
Original languageEnglish
Pages (from-to)321-331
Number of pages11
JournalEuropean journal of heart failure
Volume24
Issue number2
Early online date9 Dec 2021
DOIs
Publication statusPublished - Feb 2022

Keywords

  • Heart failure
  • Spironolactone
  • Atrial remodelling
  • Collagen cross-linking
  • PRESERVED EJECTION FRACTION
  • MAGNETIC-RESONANCE
  • EXERCISE CAPACITY
  • VOLUME
  • FIBROSIS
  • FIBRILLATION
  • DYSFUNCTION
  • SURVIVAL

Cite this